John E Hale

US Patent:

6965012, Nov 15, 2005

Filed:

Mar 20, 2000

Appl. No.:

09/936024

Inventors:

Gerald Wayne Becker - Fishers IN, US
Fredric Jay Cohen - Newtown PA, US
John Edward Hale - Fishers IN, US
Radmila Micanovic - Indianapolis IN, US
Christy Michelle Newton - Indianapolis IN, US
Timothy Wayne Noblitt - Fishers IN, US
Radhakrishnan Rathnachalam - Carmel IN, US
Sheng-Hung Rainbow Tschang - Carmel IN, US
Derrick Ryan Witcher - Fishers IN, US
Victor John Wroblewski - Carmel IN, US

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

C07K014/705
C07H021/04

US Classification:

530350, 536 235

Abstract:

Disclosed are polypeptide analogs of FLINT, polydeoxynucleotides encoding FLINT analogs, and methods of using FLINT analogs and polydeoxynucleotides. The FLINT analogs of the invention include polypeptides having the amino acid sequence of FLINT, modified at one or more positions with amino acid substitutions, and include fragments thereof, as well as Fc fusions comprising FLINT and FLINT analogs.

US Patent:

7101968, Sep 5, 2006

Filed:

Sep 3, 2003

Appl. No.:

10/654062

Inventors:

John Hale - Fishers IN, US
Michael Knierman - Indianapolis IN, US

Assignee:

Indiana Proteomics Consortium LLC - Indianapolis IN

International Classification:

C07K 1/00

US Classification:

530345

Abstract:

The present invention relates generally to the field of analyzing proteins and more specifically to the reduction and alkylation of protein samples during protein analysis. A novel composition and method for reducing and alkylating proteins is disclosed. A novel reagent including a combination of a volatile reducing agent, a volatile alkylating agent, and a volatile solvent is used for a one-step reduction and alkylation of proteins allowing the protein sample to remain in the same container during the reduction and alkylation processes.

US Patent:

7409880, Aug 12, 2008

Filed:

Mar 24, 2006

Appl. No.:

11/388722

Inventors:

John E. Hale - Fishers IN, US
Michael D. Knierman - Indianapolis IN, US
Kirk S. Boraas - Chaska MN, US

Assignee:

Indiana Proteomics Consortium, LLC - Indianapolis IN

International Classification:

B01L 3/02
G01N 37/00

US Classification:

7386401, 7386491

Abstract:

A robotic system for handling components during chromatographic analysis of a sample includes a holder for positioning a sample within a separation pathway, the holder including a first opening having an internally tapered shape and a second opening having an externally tapered shape. An interior of the holder, between the first and second openings, defines the separation pathway. A hollow rigid member has an externally tapered shape, and a receiving portion has an internally tapered shape. The holder is positioned between the hollow rigid member and the receiving portion, wherein the externally tapered hollow rigid member engages the internally tapered first opening and the internally tapered receiving portion receives the externally tapered second opening to provide a sealed separation pathway extending from the hollow rigid member to the receiving portion.

US Patent:

20030073621, Apr 17, 2003

Filed:

Apr 2, 2001

Appl. No.:

09/824438

Inventors:

John Hale - Fishers IN, US
Mark Heiman - Indianapolis IN, US
Brigitte Schoner - Monrovia IN, US
Jon Butler - Pendleton IN, US
William Heath - Fishers IN, US
Gerald Becker - Fishers IN, US
Alexander Varshavsky - Carmel IN, US

International Classification:

A61K038/17
C07K014/435

US Classification:

514/012000, 530/324000, 530/333000

Abstract:

The invention provides isolated nucleic acids, vectors, transformed host cells, analogs, functional fragments, and fusion proteins, related to beta-lipotropin. Also provided are pharmaceutical compositions comprising beta-lipotropin or fragments and/or analogs thereof, and methods for treating diabetes and complications associated therewith by administration of an effective amount of beta-lipotropin.

US Patent:

20050070694, Mar 31, 2005

Filed:

Aug 15, 2002

Appl. No.:

10/484790

Inventors:

John Hale - Fishers IN, US
Kristine Kikly - Fortville IN, US
Derrick Witcher - Fishers IN, US

International Classification:

C07K016/24

US Classification:

530388230

Abstract:

Human monoclonal antibodies that specifically bind to TNFSF13b polypeptides are disclosed. These antibodies have high affinity for hTNFSF13b (e.g., K=10M or less), a slow off rate for TNFSF13b dissociation (e.g., K=10secor less) and neutralize TNFSF13b activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13b activity in a human subject suffering from a disorder in which hTNFSF13b activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

US Patent:

20060167233, Jul 27, 2006

Filed:

Sep 9, 2005

Appl. No.:

11/223059

Inventors:

John Hale - Fishers IN, US
Michael Knierman - Indianapolis IN, US

International Classification:

C07K 14/00

US Classification:

530402000

Abstract:

The present invention relates generally to the field of analyzing proteins and more specifically to the reduction and alkylation of protein samples during protein analysis. A novel composition and method for reducing and alkylating proteins is disclosed. A novel reagent including a combination of a volatile reducing agent, a volatile alkylating agent, and a volatile solvent is used for a one-step reduction and alkylation of proteins allowing the protein sample to remain in the same container during the reduction and alkylation processes.

US Patent:

20080175841, Jul 24, 2008

Filed:

Dec 7, 2007

Appl. No.:

11/952363

Inventors:

John Edward Hale - Fishers IN, US
Kristine K. Kikly - Fortville IN, US
Derrick Ryan Witcher - Fishers IN, US

International Classification:

A61K 39/395
A61P 43/00

US Classification:

4241351, 4241721

Abstract:

Human monoclonal antibodies that specifically bind to TNFSF13polypeptides are disclosed. These antibodies have high affinity for hTNFSF13(e.g., K=10M or less), a slow off rate for TNFSF13dissociation (e.g., K=10or less) and neutralize TNFSF13activity in vitro and in vivo. The antibodies of the invention are useful in one embodiment for inhibiting TNFSF13activity in a human subject suffering from a disorder in which hTNFSF13activity is detrimental. Nucleic acids encoding the antibodies of the present invention, as well as, vectors and host cells for expressing them are also encompassed by the invention.

US Patent:

55941010, Jan 14, 1997

Filed:

Mar 3, 1995

Appl. No.:

8/398021

Inventors:

Gerald W. Becker - Fishers IN
John E. Hale - Fishers IN
Warren C. MacKellar - Plainfield IN

Assignee:

Eli Lilly and Company - Indianapolis IN

International Classification:

A61K 3800
C07K 512
C07K 1400

US Classification:

530317

Abstract:

The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.